Palmer's Point Versus The Umbilicus As Routine Primary Entry Site In Gynecologic Laparoscopy
NCT ID: NCT04216979
Last Updated: 2020-07-17
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
96 participants
INTERVENTIONAL
2019-12-15
2020-07-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Postoperative Pain Score of Laparoscopic Gynecological Surgeries
NCT05296928
Total Laparoscopic Hysterectomy vs Minilap Hysterectomy
NCT03251677
The Effect of Different Physiotherapy Methods Applied After Gynecological Abdominal Surgery on Postoperative Symptoms
NCT06965595
Safe Laparoscopic Access in Patients With Previous Abdominal and Pelvic Surgery
NCT05565508
Laparoscopic Versus Vaginal Cuff Closure During LH in Benign Gynecological Lesions
NCT05823935
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
1\. History taking Patients are randomly arranged in 2 groups Group (A):- Palmer's point is the primary entry site. The stomach will be emptied of secretions and air following endotracheal intubation. (This is most easily performed using a nasogastric tube.) The left upper quadrant will be inspected for scars and the upper abdomen palpated for hepatomegaly or splenomegaly. A 10-mm incision will be made over Palmer's point. Veress needle first will be used for insufflation and tests of safety will be considered.
A 10-mm port will be held vertically and the layers observed via a 10-mm laparoscope. A gentle rotating action in a vertical direction was used to allow the bladeless tip to separate the tissues.
The layers of the abdominal wall seen at Palmer's point are as follows:
* skin,
* subcutaneous fat,
* external oblique aponeurosis,
* internal oblique aponeurosis,
* transversalis muscle fibres,
* (sometimes) extraperitoneal fat,
* peritoneum. Once the peritoneum will be breached, the introducer will be carefully removed from the port. The laparoscope will be then reintroduced.
An extra 360° check was then performed to exclude a through-and-through bowel injury. The umbilicus was then inspected and any adhesions cleared using one or more 5-mm ports inserted under direct vision. At the end of the operation, the skin was closed using a single subcuticular suture Group (B):- The umbilicus is the primary entry site. First of all, the umbilicus is well cleaned with a piece of gauze with betadine or alcohol then small incision is done (10mm) in the umbilicus, veress needle is then inserted and tests of safety of intraperotineal insufflation are considered. 10 mm port is then introduced with gentle rotating action in a vertical direction to allow the bladeless tip to separate the tissues.
The layers of the abdominal wall seen at Palmer's point are as follows:
* skin
* linea alba
* peritoneum. Once the peritoneum is breached, the trocar will be carefully removed from the port. The laparoscope will then reintroduced.
An extra 360° check was then performed to exclude a through-and-through bowel injury. At the end of the operation, the skin will be closed using a single subcuticular suture
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
randomization
Patients are randomly arranged in 2 groups Group (A):- Palmer's point is the primary entry site. Group (B):- The umbilicus is the primary entry site.
laparoscopy entry policy
Patients will be randomly arranged in 2 groups Group (A):- Palmer's point is the primary entry site.
Group (B):- The umbilicus is the primary entry site.
group A
these are the patient with palmars point as primary entry site
laparoscopy entry policy
Patients will be randomly arranged in 2 groups Group (A):- Palmer's point is the primary entry site.
Group (B):- The umbilicus is the primary entry site.
group B
these are the patient with umbilicus as primary entry site
laparoscopy entry policy
Patients will be randomly arranged in 2 groups Group (A):- Palmer's point is the primary entry site.
Group (B):- The umbilicus is the primary entry site.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
laparoscopy entry policy
Patients will be randomly arranged in 2 groups Group (A):- Palmer's point is the primary entry site.
Group (B):- The umbilicus is the primary entry site.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Hepatomegaly
* previous left upper quadrant surgery.
* midline laparotomy
* umbilical surgery
* presence of umbilical hernia
10 Years
60 Years
FEMALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Zagazig University
OTHER_GOV
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
basem mohamed hamed khalil
lecturer of obstetrics and gynecology/ MD ob/gyn
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Zagazig University
Zagazig, East, Egypt
Zagazig
Zagazig, East, Egypt
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
5806-15-12-2019
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.